Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Cost of Revenue: 2014-2017

Historic Cost of Revenue for Theravance Biopharma (TBPH) over the last 4 years, with Dec 2017 value amounting to $6.0 million.

  • Theravance Biopharma's Cost of Revenue rose 46.19% to $826,000 in Q1 2018 from the same period last year, while for Mar 2018 it was $6.3 million, marking a year-over-year increase of 134.65%. This contributed to the annual value of $6.0 million for FY2017, which is 108.36% up from last year.
  • Theravance Biopharma's Cost of Revenue amounted to $6.0 million in FY2017, which was up 108.36% from $2.9 million recorded in FY2016.
  • Theravance Biopharma's 5-year Cost of Revenue high stood at $6.0 million for FY2017, and its period low was $2.9 million during FY2016.
  • For the 3-year period, Theravance Biopharma's Cost of Revenue averaged around $4.5 million, with its median value being $4.7 million (2015).
  • Per our database at Business Quant, Theravance Biopharma's Cost of Revenue tumbled by 37.86% in 2016 and then skyrocketed by 108.36% in 2017.
  • Yearly analysis of 4 years shows Theravance Biopharma's Cost of Revenue stood at $4.1 million in 2014, then rose by 14.76% to $4.7 million in 2015, then slumped by 37.86% to $2.9 million in 2016, then soared by 108.36% to $6.0 million in 2017.